Adjuvant Chemotherapy Guidance in Young Breast Cancer Patients With Luminal Subtypes and Stage pT1N0
Copyright © 2019 Elsevier Inc. All rights reserved..
BACKGROUND: This study evaluated whether young breast cancer patients (≤ 40 y of age) with luminal subtypes and stage pT1N0 can benefit from chemotherapy (CHT).
MATERIALS AND METHODS: This study included 688 patients aged ≤ 40 y with luminal subtypes and stage pT1N0 breast cancer. The overall survival and disease-free survival (DFS) rates in the whole cohort and subgroups were compared between patients receiving CHT followed by endocrinotherapy (ET) (CHT→ET group) and those receiving only ET (ET-alone group).
RESULTS: Univariate analysis identified that the tumors in the CHT→ET group were more aggressive than those in the ET-alone group. However, the overall survival and DFS rates did not differ significantly between the CHT→ET and ET-alone groups (P = 0.416 and 0.21, respectively), implying that a subgroup of patients could benefit from CHT. Subgroup analysis of DFS rates revealed that patients with human epidermal growth factor receptor 2 overexpression (P = 0.042), histological classification grade 3 (P = 0.030), progesterone receptor ≤ 20% (P = 0.033), and clinical stage T1c (P = 0.038) could benefit from CHT. Further analysis showed that these four risk factors combined predicted whether the patient could benefit from CHT.
CONCLUSIONS: Young patients with hormone receptor-positive and stage pT1N0 breast cancer may benefit from CHT only if they exhibit at least two of the following risk factors: progesterone receptor ≤ 20%, human epidermal growth factor receptor 2 overexpression, histological grading 3, or clinical stage T1c.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:240 |
|---|---|
| Enthalten in: |
The Journal of surgical research - 240(2019) vom: 15. Aug., Seite 165-174 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qiu, Juanjuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2020 Date Revised 14.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jss.2019.01.059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295735791 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295735791 | ||
| 003 | DE-627 | ||
| 005 | 20231225084312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jss.2019.01.059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0985.xml |
| 035 | |a (DE-627)NLM295735791 | ||
| 035 | |a (NLM)30951993 | ||
| 035 | |a (PII)S0022-4804(19)30061-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qiu, Juanjuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant Chemotherapy Guidance in Young Breast Cancer Patients With Luminal Subtypes and Stage pT1N0 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2020 | ||
| 500 | |a Date Revised 14.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: This study evaluated whether young breast cancer patients (≤ 40 y of age) with luminal subtypes and stage pT1N0 can benefit from chemotherapy (CHT) | ||
| 520 | |a MATERIALS AND METHODS: This study included 688 patients aged ≤ 40 y with luminal subtypes and stage pT1N0 breast cancer. The overall survival and disease-free survival (DFS) rates in the whole cohort and subgroups were compared between patients receiving CHT followed by endocrinotherapy (ET) (CHT→ET group) and those receiving only ET (ET-alone group) | ||
| 520 | |a RESULTS: Univariate analysis identified that the tumors in the CHT→ET group were more aggressive than those in the ET-alone group. However, the overall survival and DFS rates did not differ significantly between the CHT→ET and ET-alone groups (P = 0.416 and 0.21, respectively), implying that a subgroup of patients could benefit from CHT. Subgroup analysis of DFS rates revealed that patients with human epidermal growth factor receptor 2 overexpression (P = 0.042), histological classification grade 3 (P = 0.030), progesterone receptor ≤ 20% (P = 0.033), and clinical stage T1c (P = 0.038) could benefit from CHT. Further analysis showed that these four risk factors combined predicted whether the patient could benefit from CHT | ||
| 520 | |a CONCLUSIONS: Young patients with hormone receptor-positive and stage pT1N0 breast cancer may benefit from CHT only if they exhibit at least two of the following risk factors: progesterone receptor ≤ 20%, human epidermal growth factor receptor 2 overexpression, histological grading 3, or clinical stage T1c | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Endocrinotherapy | |
| 650 | 4 | |a HER2 overexpression | |
| 650 | 4 | |a Progesterone receptor | |
| 650 | 4 | |a Risk model | |
| 650 | 4 | |a histological grade 3 | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 700 | 1 | |a Du, Zhenggui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yuting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Junhui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Pengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Qing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of surgical research |d 1961 |g 240(2019) vom: 15. Aug., Seite 165-174 |w (DE-627)NLM000042676 |x 1095-8673 |7 nnns |
| 773 | 1 | 8 | |g volume:240 |g year:2019 |g day:15 |g month:08 |g pages:165-174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jss.2019.01.059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 240 |j 2019 |b 15 |c 08 |h 165-174 | ||